Tissue K+ in Primary Hyperaldosteronism

Primary Hyperaldosteronism Clinical Trial

Official title: Changes in Tissue Potassium Amount Before and After Treatment of Primary Hyperaldosteronism Assessed by 39K-MRI

Status Recruiting

Clinical Trial Summary

Recent human studies found tissue sodium storage in patients with hyperaldosteronism that could be detected non-invasively by 23Na-MRI. Tissue sodium accumulation could be mobilized upon treatment of hyperaldosteronism. Besides, former animal studies applying chemical electrolyte analysis indicate that this aldosterone induced sodium storage might be accompanied by intracellular potassium loss. Wether such an intracellular tissue Potassium loss occurs in vivo in patients with hyperaldosteronism and if this deficiency can be corrected by treatment is unclear. The investigators will employ 39K-MR Imaging at 7Tesla to further assess this hypothesis.

Clinical Trial Description

Patients diagnosed with primary hyperaldosteronism will be investigated using 23Na-MRI and 39K-MRI at 7 Tesla to assess tissue sodium and potassium content. Measurements will be conducted before treatment of hyperaldosteronism and three months after adrenal surgery or medical treatment (Spironolactone or Eplerenone). Furthermore, blood pressure, body water distribution (by bioimpedance spectroscopy), serum electrolytes as well as monocyte function will be assessed. ;

Related Conditions & MeSH terms

• Electrolyte Disturbance
• Hyperaldosteronism
• Primary Hyperaldosteronism

• NCT number: NCT04251780
• Study type: Interventional
• Source: University of Erlangen-Nürnberg Medical School
• Contact: Christoph Kopp, MD
• Phone: +4991318539002
• Email: christoph.kopp@uk-erlangen.de
• Status: Recruiting
• Phase: N/A
• Start date: January 1, 2018
• Completion date: December 31, 2023